Ckd Bio (063160) - Total Assets
Based on the latest financial reports, Ckd Bio (063160) holds total assets worth ₩293.05 Billion KRW (≈ $198.60 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ckd Bio - Total Assets Trend (2008–2025)
This chart illustrates how Ckd Bio's total assets have evolved over time, based on quarterly financial data. Also see how much is Ckd Bio worth for the company's overall valuation and market capitalisation.
Ckd Bio - Asset Composition Analysis
Current Asset Composition (December 2025)
Ckd Bio's total assets of ₩293.05 Billion consist of 45.4% current assets and 54.6% non-current assets. Review 063160 current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0.5% |
| Accounts Receivable | ₩34.71 Billion | 11.6% |
| Inventory | ₩96.77 Billion | 32.3% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩5.58 Billion | 1.9% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Ckd Bio's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Ckd Bio stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ckd Bio's current assets represent 45.4% of total assets in 2025, a decrease from 60.8% in 2008.
- Cash Position: Cash and equivalents constituted 0.5% of total assets in 2025, down from 9.6% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is inventory at 32.3% of total assets.
Ckd Bio Competitors by Total Assets
Key competitors of Ckd Bio based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
China | CN¥22.22 Billion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
IS:ECILC
|
Turkey | TL70.69 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥10.50 Billion |
|
Teyi Pharmaceutical Group Co Ltd
SHE:002728
|
China | CN¥2.33 Billion |
Ckd Bio - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.06 | 1.26 | 1.85 |
| Quick Ratio | 0.33 | 0.39 | 0.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩7.42 Billion | ₩26.62 Billion | ₩44.60 Billion |
Ckd Bio - Advanced Valuation Insights
This section examines the relationship between Ckd Bio's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.62 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 5.4% |
| Total Assets | ₩299.87 Billion |
| Market Capitalization | $47.59 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ckd Bio's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Ckd Bio's assets grew by 5.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ckd Bio (2008–2025)
The table below shows the annual total assets of Ckd Bio from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩299.87 Billion ≈ $203.22 Million |
+5.40% |
| 2024-12-31 | ₩284.49 Billion ≈ $192.80 Million |
-3.16% |
| 2023-12-31 | ₩293.79 Billion ≈ $199.09 Million |
-6.02% |
| 2022-12-31 | ₩312.59 Billion ≈ $211.84 Million |
+4.71% |
| 2021-12-31 | ₩298.54 Billion ≈ $202.32 Million |
+5.32% |
| 2020-12-31 | ₩283.46 Billion ≈ $192.10 Million |
+21.48% |
| 2019-12-31 | ₩233.35 Billion ≈ $158.14 Million |
+26.46% |
| 2018-12-31 | ₩184.52 Billion ≈ $125.05 Million |
+2.81% |
| 2017-12-31 | ₩179.48 Billion ≈ $121.63 Million |
-0.79% |
| 2016-12-31 | ₩180.91 Billion ≈ $122.60 Million |
+6.02% |
| 2015-12-31 | ₩170.64 Billion ≈ $115.64 Million |
+3.38% |
| 2014-12-31 | ₩165.07 Billion ≈ $111.86 Million |
-5.94% |
| 2013-12-31 | ₩175.50 Billion ≈ $118.93 Million |
-5.35% |
| 2012-12-31 | ₩185.42 Billion ≈ $125.66 Million |
-6.49% |
| 2011-12-31 | ₩198.29 Billion ≈ $134.38 Million |
+67.66% |
| 2010-12-31 | ₩118.27 Billion ≈ $80.15 Million |
+6.30% |
| 2009-12-31 | ₩111.26 Billion ≈ $75.40 Million |
+17.30% |
| 2008-12-31 | ₩94.85 Billion ≈ $64.28 Million |
-- |
About Ckd Bio
CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also e… Read more